Effect of Cardiopeptin on NT-proBNP Levels,Adverse Reactions in Pa-tients with Chronic Congestive Heart Failure
Objective To analyze the effects of cardiopeptin on N-terminal pro-brain natriuretic peptide(NT-proBNP)levels,adverse reactions in patients with chronic congestive heart failure.Methods 100 patients with chronic congestive heart failure admitted to Liangshan County People's Hospital from February 2020 to March 2023 were the study subjects,and were divided into the control group(torasemide + spironolactone + valacyclovir extended-release tablets)and the observation group(combined with injection of recombinant human brain natriuretic peptide on the ba-sis of the control group)by random number table method with 50 cases in each group.And the NT-proBNP level,ad-verse reactions and other indexes of the two groups after treatment were compared and analyzed.Results After treat-ment,the left ventricular ejection fraction of the observation group was higher than that of the control group,and the left ventricular end-systolic dimension,global longitudinal strain,totall longitudinal strain and left ventricular end-diastolic dimension scores were lower than those of the control group,and the differences were statistically significant(all P<0.05).The NT-proBNP level of patients in the observation group(580.21±17.71)ng/L was lower than that of the control group(603.32±18.89)ng/L after treatment,and the difference was statistically significant(t=6.251,P<0.05),and there was no statistical significance difference of the incidence of adverse reactions in the observation group(10.00%)and the control group(6.00%)(P>0.05).Conclusion The effect of cardiopeptin on the treatment of patients with chronic congestive heart failure is better,the NT-proBNP level of the patients is lower,and the cardiac function level of the patients is higher,and the incidence of adverse reactions is low,and the comprehensive application of this treatment is of higher value.
万方数据
维普
